Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Launched by RIGSHOSPITALET, DENMARK · May 24, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
PET imaging with 18F-FDG is a well established method for non invasively assessing the intracellular glucose accumulation. 18F-FDG PET is used in many applications with diagnosing and staging of patients with cancer being one of the primary indications. Once internalized into the cell, 18F-FDG is phosphorylated to the metabolically inactive 18F-FDG-6-phosphate. Therefore it is not possible to determine what happens to the downstream glucose metabolites. In particular, it is not possible to determine the conversion into lactate, which is upregulated in many cancers. The upregulation of lacta...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with breast cancer, gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) grades G1, G2 or G3, lymphoma or sarcoma
- • Measurable solid tumor of at least 1.5 cm
- • Capable of understanding the patient information in Danish and giving full informed consent
- Exclusion Criteria:
- • Pregnancy
- • Breast-feeding
- • Weighs above 140 kg and/or with abdominal circumference exceeding the gantry of the PET/MR coil (120 cm)
- • History of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FDG or pyruvate
- • Patients who are unable to lie in the MR scanner for up to 90 minutes
- • Pace-maker
- • Metallic implantations within the past 6 weeks
- • Non-MR compatible implants
- • Claustrophobia
- • Participants who have not fasted for a minimum of 4 hours prior to the planned scan time
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Copenhagen, , Denmark
Patients applied
Trial Officials
Mathias Loft, MD
Principal Investigator
Rigshospitalet, Denmark
Andreas Kjaer, MD
Study Director
Rigshospitalet, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials